Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses
Journal of Virology · 2025
DOI: 10.1128/jvi.00903-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Zhulong Hu und 30 weiteren Autor:innen. Beteiligte Einrichtung: Patronus Biotech Co. Ltd., Guangzhou, China. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Viral Fusion Proteins, Nanoparticles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Respiratory syncytial virus (RSV) is a global public health concern. Currently, RSV vaccines are approved only for use in older adults, while preventing the disease in infants and children, as well as ensuring vaccine durability, remains a significant challenge. The pre-fusion conformation of the RSV fusion (F) glycoprotein is a primary target for vaccine development, as it elicits significantly higher neutralizing antibody titers than the post-fusion form. Here, we conjugated either the first-generation RSV pre-fusion F antigen, DS-Cav1, or the second-generation antigen, Sc9-10, to a computationally designed nanoparticle platform, NPM, via a Catcher/Tag system. Conjugating RSV pre-fusion F to NPM significantly enhanced immunogenicity, stability, and bioactivity compared to display on the I53-50 nanoparticle platform. In a cotton rat challenge model, Sc9-10-NPM vaccine candidates provided effective protection across a wide dosage range, regardless of the adjuvant used. These results support the continued development of this promising nanoparticle-based RSV vaccine candidate. IMPORTANCE Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness in infants and young children worldwide, yet few vaccines are approved for use in these vulnerable groups. In this study, we developed a new vaccine candidate based on a second-generation RSV pre-fusion F protein, engineered for improved stability and immune response. This protein was displayed on a specially designed nanoparticle platform to enhance its effectiveness and durability. The vaccine elicited strong immune responses and provided complete protection in preclinical models, even without the use of potent adjuvants that may cause side effects. Importantly, it did not trigger adverse vaccine-enhanced disease (VED). These findings suggest that this vaccine design could offer a safer and more effective way to protect infants and other at-risk populations from RSV. Additionally, the nanoparticle platform may be applicable to vaccines against other infectious diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Patronus Biotech Co. Ltd., Guangzhou, China.
- State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Wuhan, China.
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou…
- Guangzhou National Laboratory, Bio-Island, Guangzhou, China.
- Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Di…
- Pediatric Research Institute, Children's Hospital of Chongqing Medical University, Chongqing, China.
ORCID-Profile: Enmei Liu, Jincun Zhao, Yuanyuan Li, Jing Jin
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Hu, Z., Tian, S., Zhou, Y., Wang, Y., Li, Y., Zhang, S., Wei, P., Zhuang, Z., Ren, L., Liu, J., Zang, N., Yu, R., Ding, Y., Guo, Y., Jing, C., Chen, H., Zhang, C., Yao, Y., Deng, C., …, & Jin, J. (2025). Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses. Journal of Virology. https://doi.org/10.1128/jvi.00903-25
Vancouver
Hu Z, Tian S, Zhou Y, Wang Y, Li Y, Zhang S, et al. Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses. Journal of Virology. 2025. doi:10.1128/jvi.00903-25
BibTeX
@article{Hu2025,
author = {Hu, Zhulong and Tian, Siyu and Zhou, Yu and Wang, Yanqun and Li, Yu and Zhang, Senyan and Wei, Peilan and Zhuang, Zhen and Ren, Luo and Liu, Jiao and Zang, Na and Yu, Rui and Ding, Yanbin and Guo, Yan and Jing, Cai and Chen, Hang and Zhang, Caixia and Yao, Yuanfeng and Deng, Chunping and Wei, Rui and Zhou, Peng and Zou, Yongjuan and Zhao, Dawei and Liu, Shuyun and Fu, Meijuan and Mo, Xuejun and Peng, Guodong and Liu, Enmei and Zhao, Jincun and Li, Yuanyuan and Jin, Jing},
title = {Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses},
journal = {Journal of Virology},
year = {2025},
doi = {10.1128/jvi.00903-25}
}
EUVIMED